Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | -37.25% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.42 | N/A | -37.25% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing operational hurdles. They remain committed to their long-term goals, indicating a cautious approach moving forward.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategy despite current setbacks.
Terns Pharmaceutical's earnings report shows a significant miss on EPS, which reflects ongoing challenges in their operations. Despite this, the stock rose by 5.34%, likely driven by investor optimism or other market factors. The lack of revenue data and guidance leaves uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROIVANT SCIENCES LTD
Nov 13, 2023